UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $10.77 Million Stake in Haemonetics Corporation $HAE

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Haemonetics Corporation (NYSE:HAE) by 5.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 143,611 shares of the medical instruments supplier’s stock after acquiring an additional 7,914 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.32% of Haemonetics worth $10,771,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of HAE. AQR Capital Management LLC grew its position in shares of Haemonetics by 48.6% in the 4th quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier’s stock valued at $253,523,000 after purchasing an additional 1,034,226 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in Haemonetics by 994.7% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock worth $110,615,000 after buying an additional 1,254,035 shares during the period. Dimensional Fund Advisors LP lifted its stake in Haemonetics by 21.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after buying an additional 233,119 shares in the last quarter. North Peak Capital Management LLC boosted its holdings in shares of Haemonetics by 204.4% in the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock valued at $88,405,000 after buying an additional 740,626 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH increased its position in shares of Haemonetics by 17.3% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 841,017 shares of the medical instruments supplier’s stock worth $47,400,000 after acquiring an additional 124,020 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on HAE. BTIG Research boosted their price objective on shares of Haemonetics from $96.00 to $110.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Mizuho lifted their price target on Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Robert W. Baird upped their price objective on Haemonetics from $96.00 to $119.00 and gave the stock an “outperform” rating in a research report on Friday, August 21st. Wall Street Zen upgraded Haemonetics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Finally, JPMorgan Chase & Co. lifted their target price on Haemonetics from $62.00 to $86.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $99.78.

Haemonetics Price Performance

NYSE:HAE opened at $103.00 on Monday. Haemonetics Corporation has a 52-week low of $47.31 and a 52-week high of $109.57. The company has a market cap of $4.69 billion, a P/E ratio of 50.49, a P/E/G ratio of 2.06 and a beta of 0.54. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.91 and a current ratio of 3.08. The stock’s 50-day simple moving average is $87.71 and its 200 day simple moving average is $71.62.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 EPS for the quarter, beating the consensus estimate of $1.08 by $0.06. The firm had revenue of $339.38 million during the quarter, compared to analysts’ expectations of $327.86 million. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%.The business’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.10 earnings per share. As a group, sell-side analysts forecast that Haemonetics Corporation will post 5.29 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.